We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA cited a Montreal drugmaker for refusing to allow an FDA inspector to take photographs during an inspection — and said that alone can lead to a finding that products are adulterated. Read More
The Ohio Taxpayers for Lower Drug Prices advocacy group accuses drugmakers of making donations aimed at influencing an election, meeting the definition of a political action committee. Read More
The FDA warned a Chinese drugmaker for inadequate testing and quality control for drug supplies and finished products, as well as numerous other GMP violations. Read More
Insys Pharmaceuticals settled with the state of Illinois for $4.45 million to settle a 2016 lawsuit over the company’s deceptive marketing of opioids, the state attorney general announced. Read More